Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

E. S. Antonarakis; A. J. Armstrong

doi:10.1038/pcan.2011.24

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

E. S. Antonarakis, A. J. Armstrong

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

Original language	English (US)
Pages (from-to)	206-218
Number of pages	13
Journal	Prostate Cancer and Prostatic Diseases
Volume	14
Issue number	3
DOIs	https://doi.org/10.1038/pcan.2011.24
State	Published - Sep 2011

Keywords

castrate-resistant prostate cancer
clinical trials
drug development
novel therapies

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

Access to Document

10.1038/pcan.2011.24

Cite this

@article{9bf1b7b9891f4f6fa4ef65d1e353d5d6,

title = "Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer",

abstract = "Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.",

keywords = "castrate-resistant prostate cancer, clinical trials, drug development, novel therapies",

author = "Antonarakis, {E. S.} and Armstrong, {A. J.}",

year = "2011",

month = sep,

doi = "10.1038/pcan.2011.24",

language = "English (US)",

volume = "14",

pages = "206--218",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

AU - Antonarakis, E. S.

AU - Armstrong, A. J.

PY - 2011/9

Y1 - 2011/9

N2 - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

AB - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

KW - castrate-resistant prostate cancer

KW - clinical trials

KW - drug development

KW - novel therapies

UR - http://www.scopus.com/inward/record.url?scp=80054749674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054749674&partnerID=8YFLogxK

U2 - 10.1038/pcan.2011.24

DO - 10.1038/pcan.2011.24

M3 - Review article

C2 - 21577233

AN - SCOPUS:80054749674

VL - 14

SP - 206

EP - 218

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 3

ER -

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this